Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment
Glioblastoma is a highly aggressive and difficult-to-treat brain cancer that resists conventional therapies.
Glioblastoma is a highly aggressive and difficult-to-treat brain cancer that resists conventional therapies. Recent advances in chimeric antigen receptor (CAR) T-cell therapy have shown promising potential for treating glioblastoma; however, achieving optimal efficacy remains challenging due to tumor antigen heterogeneity, the tumor microenvironment, and T-cell exhaustion. In this study, we developed a mathematical model of CAR T-cell therapy for glioblastoma to explore combinatorial antigen targeting with multiple CAR T-cell treatments that take into account the spatial heterogeneity of antigen expression.
Demonstrates the need for improved therapeutic strategies against the most lethal brain tumour.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma